Professor Robert Chunhua Zhao from the Chinese Academy of Medical
Sciences is Executive Director of the National Center for Stem Cell
Research. His group has taken stem cell therapy into phase II clinical
trials in China, and is the leading runner in stem cell therapeutics.
They have identified a mesenchymal stem cell (MSC) population from
human fetal bone marrow and found that these cells could differentiate
not only into osteogenic, adipogenic and endothelial lineages, but also
hepatocyte-like cells, and neural and erythroid cells.
They remained in
some tissues and organs during gestation and could give rise to
different kinds of pluripotent stem cells and thus could potentially
contribute to self-repair and self-renewal of tissues and organs. They
generated cells not only for the damaged tissues in which they reside,
but also for damaged tissues at other locations in the body via
migration triggered by proinflammatory cytokines and growth factors.
The potential use of MSCs in tissue regeneration has been shown in
several models, including skin, muscle, lung, heart and the small
intestine.
MSCs have emerged as a promising therapeutic modality for
tissue regeneration and autoimmune disease, although the mechanisms
underlying the immune-modulatory effects of MSCs have not yet been
clearly defined.
Proinflammatory cytokines와 growth factors이 MSCs의 migration을 trigger하는데 필요하다는 게
요점입니다.
그러면 도대체 어떤 proinflammatory cytokines와 growth factors 인지가 중요한 것이겠지요.
댓글 없음:
댓글 쓰기